Verrica Pharmaceuticals Inc. Common Stock
VRCA
VRCA: Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.
moreShow VRCA Financials
Recent trades of VRCA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VRCA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Ampule crush tool Apr. 11, 2023
-
Patent Title: Quantification and preparation of pharmaceutical grade cantharidin Nov. 09, 2021
-
Patent Title: Treatment of cutaneous disorders Oct. 19, 2021
-
Patent Title: Compositions, methods and systems for the treatment of cutaneous disorders Jul. 06, 2021
-
Patent Title: Applicator Oct. 27, 2020
-
Patent Title: Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives Aug. 18, 2020
Federal grants, loans, and purchases
Followers on VRCA's company Twitter account
Number of mentions of VRCA in WallStreetBets Daily Discussion
Recent insights relating to VRCA
Recent picks made for VRCA stock on CNBC
ETFs with the largest estimated holdings in VRCA
Flights by private jets registered to VRCA